506 related articles for article (PubMed ID: 26010016)
1. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
Tellor KB; Patel S; Armbruster AL; Daly MW
J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
7. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
8. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.
Lee HF; Chan YH; Tu HT; Kuo CT; Yeh YH; Chang SH; Wu LS; See LC
Int J Cardiol; 2018 Jun; 261():78-83. PubMed ID: 29559181
[TBL] [Abstract][Full Text] [Related]
12. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
Alosaimi HM; Alqahtani S; Balkhi B; Alqahtani M; Alzamil F; Alhossan A; Alqahtany FS; Alharbi AA; Alqahtani NA; Albackr H; Elgohary G; Algahtani FH
PeerJ; 2022; 10():e13974. PubMed ID: 36105646
[TBL] [Abstract][Full Text] [Related]
15. Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.
Evans A; Davies M; Osborne V; Roy D; Shakir S
PLoS One; 2020; 15(10):e0240489. PubMed ID: 33035259
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
[TBL] [Abstract][Full Text] [Related]
17. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
[TBL] [Abstract][Full Text] [Related]
18. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
19. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
20. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Yagi N; Suzuki S; Arita T; Otsuka T; Semba H; Kano H; Matsuno S; Kato Y; Uejima T; Oikawa Y; Yajima J; Matsuhama M; Yamashita T
Heart Vessels; 2020 Jan; 35(1):110-117. PubMed ID: 31222552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
